Effect of Dapagliflozin on Kidney and Cardiovascular Outcomes by Baseline KDIGO Risk Categories
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Diabetologia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
Diabetologia 2022 Jul 01;65(7)1085-1097, SW Waijer, P Vart, DZI Cherney, GM Chertow, N Jongs, AM Langkilde, JFE Mann, O Mosenzon, JJV McMurray, P Rossing, R Correa-Rotter, BV Stefansson, RD Toto, DC Wheeler, HJL HeerspinkFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.